FDA Approves First Generics of Gilotrif (afatinib) Tablets
The FDA has approved the first generic versions of Gilotrif (afatinib) for treating metastatic NSCLC with specific EGFR mutations.
Asset / Drug
Drug and asset intelligence for Gilotrif with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.